Pulmatrix, Inc. (PULM)
| Market Cap | 4.64M -79.8% |
| Revenue (ttm) | n/a |
| Net Income | -5.16M |
| EPS | -1.41 |
| Shares Out | 3.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 17,598 |
| Open | 1.230 |
| Previous Close | 1.250 |
| Day's Range | 1.230 - 1.300 |
| 52-Week Range | 1.160 - 9.370 |
| Beta | 1.94 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 26, 2026 |
About PULM
Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in ch... [Read more]
Financial Performance
Financial StatementsNews
Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger
Series B Preferred Stock investment made in Pulmatrix with a conversion price of $2.20 is a part of the ongoing merger process FRAMINGHAM, Mass., April 21, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulma...
Pulmatrix to merge with Eos Senolytix
Pulmatrix (PULM) and Eos Senolytix, a biotechnology company developing novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases, announced a definitive merger agree...
Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan
Combined company to operate as Eos SENOLYTIX, a first-in-class anti-aging biotechnology company $19 million financings to advance lead clinical candidate PTC-2105 for sarcopenia and age-related diseas...
Pulmatrix announces Cullgen terminates merger agreement
Pulmatrix (PULM) announced that on February 28, Cullgen notified Pulmatrix that Cullgen was terminating the Merger Agreement and related transactions thereunder. This termination follows the December ...
Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities
Cullgen had been seeking approval for a merger with Pulmatrix from the China Securities Regulatory Commission and on February 28, 2026, notified Pulmatrix that Cullgen was terminating the Merger Agree...
Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results
Plans to License or Monetize our Migraine and Inhalation Assets Continue FRAMINGHAM, Mass., Feb. 26, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceut...
Pulmatrix and Cullgen continue to pursue merger
Pulmatrix (PULM) and Cullgen have mutually agreed to waive the “No Solicitation” clause in the Merger Agreement signed in November 2024 in order to permit each party to explore alternate…
Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives
Pulmatrix continues to support Cullgen in seeking approval for their merger from the China Securities Regulatory Commission FRAMINGHAM, Mass. , Dec. 18, 2025 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatri...
Pulmatrix reports Q3 EPS (24c) vs. (71c) last year
Reports Q3 revenue $0 vs. $366,000 last year. Revenue decrease is primarily related to completion of the wind down of the PUR1900 Phase 2b clinical trial during the year ended…
Pulmatrix to potentially divest its patent portfolio for iSPERSE technology
Peter Ludlum, Interim CEO of Pulmatrix (PULM), commented, “Our focus in the third quarter has been to advance steps to complete the proposed merger with Cullgen, a privately held, clinical-stage…
Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets
As part of the proposed merger, Pulmatrix currently intends to divest its assets including its proprietary dry powder delivery technology, iSPERSE™, which enables delivery of small- or large-molecule ...
Pulmatrix to potentially divest its patent portfolio for iSPERSE technology
Peter Ludlum, Interim Chief Executive Officer of Pulmatrix (PULM), commented, “Our focus in the second quarter has been to advance steps to complete the proposed merger with Cullgen, a privately…
Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets
Proposed merger anticipated to close in 2025 As part of the proposed merger, Pulmatrix currently intends to divest its assets including its proprietary dry powder delivery technology, iSPERSE™, which ...
Pulmatrix trading halted, volatility trading pause
11:11 EDT Pulmatrix (PULM) trading halted, volatility trading pause
Pulmatrix trading halted, volatility trading pause
11:37 EDT Pulmatrix (PULM) trading halted, volatility trading pause
Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets
Registration statement for proposed Cullgen merger declared effective by the SEC Proposed merger anticipated to close in June As part of proposed merger, Pulmatrix currently intends to divest its asse...
PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Pulmatrix, Inc...
Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets
Announced merger agreement with Cullgen in November, anticipated to close in the first half of 2025 As part of proposed merger, Pulmatrix intends to divest its assets including its Phase 2-ready acute...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / November 15, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or b...
Pulmatrix announces merger agreement with Cullgen
Pulmatrix (PULM) announced a merger agreement with Cullgen, a privately-held, clinical-stage biopharmaceutical company applying its proprietary targeted protein degradation uSMITE platform to discover...
Pulmatrix and Cullgen Announce Proposed Merger
Merger to create a Nasdaq-listed company focusing on targeted protein degradation technology with three degrader programs in or about to initiate Phase 1 clinical trials – two for the treatment of can...
Pulmatrix trading halted, news pending
08:55 EST Pulmatrix (PULM) trading halted, news pending